QUOD Statistics October 2017 NRG(17)28 QUOD Bioresource Key Figures - PowerPoint PPT Presentation

QUOD Statistics October 2017 NRG(17)28

QUOD Bioresource Key Figures Da Date te 1 O 1 Octob tober er 20 2017 17 Donor Donors s 2, 2,591 591 Sa Sampl mples es 45, 45,48 486 i 6 in n tot total, al, inc inclu ludin ding: g: Bl Blood ood 24, 24,46 460 s 0 sam ample ples Urine Ur ine 5,6 5,675 s 5 sam ample ples Ki Kidne dney y 6,1 6,197 s 7 sam ample ples s (3,12 ,128 8 bio biopsi psies) s) Liver Li ver 3,4 3,461 s 1 sam ample ples s (1,73 ,739 9 bio biopsi psies) s) Ur Urete eter r 3,7 3,780 s 0 sam ample ples s (1,90 ,903 3 bio biopsi psies) s) Sp Splee leen n 1,9 1,913 s 3 sam ample ples s (1,91 ,913 3 bio biopsi psies) s) Un Units its 271 271,94 ,949 b 9 bio ioban bank i k items ems NRG(17)28

QUOD Donors In Total and Per Region Milestone: 2,500 donors were enrolled into the QUOD Bioresource by 22 August 2017 NRG(17)28

QUOD Samples In Total and Per Type NRG(17)28

QUOD Sample Collection Metrics NRG(17)28

QUOD Biopsy and Incident Metrics General Incidents: Clinical incidents – no significant recipient consequences or thought not to be attributable to a QUOD biopsy Serious Adverse Reactions: Clinical incidents with recipient consequences – considered as most likely due to a QUOD biopsy NRG(17)28

QUOD Biopsy and Incident Metrics General Incidents: Clinical incidents – no significant recipient consequences or thought not to be attributable to a QUOD biopsy Serious Adverse Reactions: Clinical incidents with recipient consequences – considered as most likely due to a QUOD biopsy NRG(17)28

QUOD Biopsy and Incident Metrics General Incidents: Clinical incidents – no significant recipient consequences or thought not to be attributable to a QUOD biopsy Serious Adverse Reactions: Clinical incidents with recipient consequences – considered as most likely due to a QUOD biopsy NRG(17)28

QUOD Biopsy and Incident Metrics General Incidents: Clinical incidents – no significant recipient consequences or thought not to be attributable to a QUOD biopsy Serious Adverse Reactions: Clinical incidents with recipient consequences – considered as most likely due to a QUOD biopsy NRG(17)28

QUOD Biopsy and Incident Metrics Literature References: – Peters et al (2017). Acta Radiol. 58(2):240-8. – Chunduri et al (2015). Semin Dial. 28(2):E11-4. – Furness et al (2003). Transplantation. 76(6):969-73. – Cozens et al (1992). Br J Radiol. 65(775):594-7. NRG(17)28

Consent for QUOD Research and Actual QUOD Donors — Per Month All Donors (Proc + Non) Cases in Sep ‘17: 84 Tx Consent / Auth 75 Res. Consent / Auth 67 Actual QUOD Donors NRG(17)28

Actual Organ Donors Cases in Sep ‘17: 69 Tx Consent / Auth 61 Res. Consent / Auth 59 Actual QUOD Donors Non – proceeding Donors Cases in Sep ‘17: 15 Tx Consent / Auth 14 Res. Consent / Auth 8 Actual QUOD Donors NRG(17)28

Consent for QUOD Research and Actual QUOD Donors — Step Chart NRG(17)28

Consent for QUOD Research and Actual QUOD Donors — Per SNOD Team NRG(17)28

QUOD Samples Issued to Applications NRG(17)28 – Latest issued samples (Sep’17) : RAP028 (Khorsandi), RAP030 (Brennan) – Samples were issued to 14 research applications, as complete or phased sample sets – Issued samples account to 1% of QUOD biobank items, while covering 15% of donors – Further samples will be allocated and issued to 13 approved research applications